HALO - Company ID 0001159036
HALOZYME THERAPEUTICS, INC. (HALO) reported revenue of $1.40B for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $1.40B | +37.6% |
| FY 2024 | $1.02B | +22.4% |
| FY 2023 | $829.25M | +25.6% |
| FY 2022 | $660.12M | +48.9% |
| FY 2021 | $443.31M | +65.7% |
| FY 2020 | $267.59M | +36.5% |
| FY 2019 | $195.99M | +29.1% |
| FY 2018 | $151.86M | -52.0% |
| FY 2017 |
HALOZYME THERAPEUTICS, INC. (HALO) reported revenue of $1.40B for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, HALOZYME THERAPEUTICS, INC.'s revenue grew from $56.09M to $1.40B.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $316.61M |
| +115.8% |
| FY 2016 | $146.69M | +8.6% |
| FY 2015 | $135.06M | +79.3% |
| FY 2014 | $75.33M | +37.5% |
| FY 2013 | $54.80M | +29.5% |
| FY 2012 | $42.33M | -24.5% |
| FY 2011 | $56.09M | - |